- Enhabit Home Health & Hospice (NYSE: EHAB) is set to announce its quarterly earnings on May 20, 2026, with Wall Street analysts anticipating earnings per share of $0.12 and revenue estimates around $266.66 million.
- The company has undergone significant leadership changes, with Dale Clift now serving as President and CEO, contributing to an improved investment outlook as Zacks Investment Research recently issued a “Buy” rating.
On May 20, 2026, Enhabit Home Health & Hospice (NYSE: EHAB) is set to announce its quarterly earnings. Wall Street analysts expect earnings of $0.12 per share. The consensus estimate for revenue is approximately $266.66 million for the quarter. This report follows significant recent changes within the company’s leadership and ownership structure.
Enhabit Home Health & Hospice provides home-based medical care. Following its acquisition by Kinderhook Industries, the company has a new president and CEO, Dale Clift, as highlighted by Business Wire. This leadership change occurs as the company navigates its financial performance and prepares for its upcoming earnings announcement.
Analysts show growing optimism for Enhabit Home Health & Hospice’s future earnings. Zacks Investment Research recently upgraded the stock to a “Buy” rating. This stock upgrade reflects an upward trend in earnings estimates, suggesting that experts believe the company’s financial prospects are improving ahead of the report.
The company’s valuation metrics offer a mixed view. Enhabit Home Health & Hospice has a price-to-sales ratio of 0.66. A ratio under one can indicate that a stock’s price is low compared to its revenues. Regarding its financial stability, Enhabit Home Health & Hospice has a debt-to-equity ratio of 0.87, which compares its total debt to the value owned by shareholders. The company’s current ratio is 1.56. This figure suggests it has $1.56 in short-term assets for every dollar of short-term liabilities, indicating a capacity to meet its immediate financial obligations.
